As part of the agreement, Hims said it won’t compound GLP-1 medications like Zepbound in the future.
Source: [MarketWatch](https://www.marketwatch.com/story/hims-hers-struck-a-glp-1-deal-with-lilly-its-stock-is-rallying-d06ebe60?mod=mw_rss_topstories)